vs

Side-by-side financial comparison of INTERNATIONAL BANCSHARES CORP (IBOC) and Kiniksa Pharmaceuticals International, plc (KNSA). Click either name above to swap in a different company.

INTERNATIONAL BANCSHARES CORP is the larger business by last-quarter revenue ($217.7M vs $202.1M, roughly 1.1× Kiniksa Pharmaceuticals International, plc). INTERNATIONAL BANCSHARES CORP runs the higher net margin — 62.3% vs 7.0%, a 55.3% gap on every dollar of revenue. On growth, Kiniksa Pharmaceuticals International, plc posted the faster year-over-year revenue change (65.0% vs 4.5%). INTERNATIONAL BANCSHARES CORP produced more free cash flow last quarter ($472.9M vs $53.3M). Over the past eight quarters, Kiniksa Pharmaceuticals International, plc's revenue compounded faster (59.1% CAGR vs 2.8%).

International Bancshares Corporation is a bank holding company based in Laredo, Texas whose primary subsidiary is International Bank of Commerce. Through its bank subsidiaries, it has 217 banking offices and 315 automated teller machines serving 88 communities in the U.S. states of Texas and Oklahoma.

Kiniksa Pharmaceuticals International plc is a global biopharmaceutical firm focused on discovering, developing and commercializing targeted therapies for patients with unmet medical needs, primarily in autoimmune, inflammatory and rare disease segments. It operates across major markets including North America, Europe and Asia, advancing a pipeline of clinical-stage and approved treatment candidates.

IBOC vs KNSA — Head-to-Head

Bigger by revenue
IBOC
IBOC
1.1× larger
IBOC
$217.7M
$202.1M
KNSA
Growing faster (revenue YoY)
KNSA
KNSA
+60.4% gap
KNSA
65.0%
4.5%
IBOC
Higher net margin
IBOC
IBOC
55.3% more per $
IBOC
62.3%
7.0%
KNSA
More free cash flow
IBOC
IBOC
$419.7M more FCF
IBOC
$472.9M
$53.3M
KNSA
Faster 2-yr revenue CAGR
KNSA
KNSA
Annualised
KNSA
59.1%
2.8%
IBOC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBOC
IBOC
KNSA
KNSA
Revenue
$217.7M
$202.1M
Net Profit
$106.9M
$14.2M
Gross Margin
89.6%
Operating Margin
62.8%
9.8%
Net Margin
62.3%
7.0%
Revenue YoY
4.5%
65.0%
Net Profit YoY
-7.1%
259.8%
EPS (diluted)
$1.71
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBOC
IBOC
KNSA
KNSA
Q4 25
$217.7M
$202.1M
Q3 25
$218.1M
$180.9M
Q2 25
$208.2M
$156.8M
Q1 25
$198.2M
$137.8M
Q4 24
$208.3M
$122.5M
Q3 24
$211.8M
$112.2M
Q2 24
$207.8M
$108.6M
Q1 24
$205.8M
$79.9M
Net Profit
IBOC
IBOC
KNSA
KNSA
Q4 25
$106.9M
$14.2M
Q3 25
$108.4M
$18.4M
Q2 25
$100.1M
$17.8M
Q1 25
$96.9M
$8.5M
Q4 24
$115.1M
$-8.9M
Q3 24
$99.8M
$-12.7M
Q2 24
$97.0M
$-3.9M
Q1 24
$97.3M
$-17.7M
Gross Margin
IBOC
IBOC
KNSA
KNSA
Q4 25
89.6%
Q3 25
88.8%
Q2 25
88.1%
Q1 25
87.0%
Q4 24
85.4%
Q3 24
82.1%
Q2 24
88.7%
Q1 24
86.7%
Operating Margin
IBOC
IBOC
KNSA
KNSA
Q4 25
62.8%
9.8%
Q3 25
62.6%
13.3%
Q2 25
60.5%
12.9%
Q1 25
61.1%
9.6%
Q4 24
64.2%
-15.7%
Q3 24
60.0%
-8.6%
Q2 24
60.1%
-0.1%
Q1 24
59.9%
-20.7%
Net Margin
IBOC
IBOC
KNSA
KNSA
Q4 25
62.3%
7.0%
Q3 25
49.7%
10.2%
Q2 25
48.1%
11.4%
Q1 25
48.9%
6.2%
Q4 24
71.5%
-7.3%
Q3 24
47.1%
-11.3%
Q2 24
46.7%
-3.6%
Q1 24
47.3%
-22.2%
EPS (diluted)
IBOC
IBOC
KNSA
KNSA
Q4 25
$1.71
$0.18
Q3 25
$1.74
$0.23
Q2 25
$1.61
$0.23
Q1 25
$1.56
$0.11
Q4 24
$1.85
$-0.11
Q3 24
$1.60
$-0.18
Q2 24
$1.56
$-0.06
Q1 24
$1.56
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBOC
IBOC
KNSA
KNSA
Cash + ST InvestmentsLiquidity on hand
$5.5B
$414.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.3B
$567.6M
Total Assets
$16.6B
$763.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBOC
IBOC
KNSA
KNSA
Q4 25
$5.5B
$414.1M
Q3 25
$5.6B
$352.1M
Q2 25
$5.8B
$307.8M
Q1 25
$5.6B
$268.3M
Q4 24
$5.4B
$243.6M
Q3 24
$5.8B
$223.8M
Q2 24
$5.7B
$218.8M
Q1 24
$5.7B
$213.6M
Stockholders' Equity
IBOC
IBOC
KNSA
KNSA
Q4 25
$3.3B
$567.6M
Q3 25
$3.1B
$535.4M
Q2 25
$3.0B
$495.0M
Q1 25
$2.9B
$457.5M
Q4 24
$2.8B
$438.4M
Q3 24
$2.7B
$437.0M
Q2 24
$2.6B
$435.1M
Q1 24
$2.5B
$431.9M
Total Assets
IBOC
IBOC
KNSA
KNSA
Q4 25
$16.6B
$763.6M
Q3 25
$16.6B
$712.3M
Q2 25
$16.5B
$661.1M
Q1 25
$16.3B
$599.3M
Q4 24
$15.7B
$580.6M
Q3 24
$15.9B
$555.3M
Q2 24
$15.5B
$542.4M
Q1 24
$15.4B
$519.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBOC
IBOC
KNSA
KNSA
Operating Cash FlowLast quarter
$491.1M
$53.9M
Free Cash FlowOCF − Capex
$472.9M
$53.3M
FCF MarginFCF / Revenue
217.2%
26.4%
Capex IntensityCapex / Revenue
8.3%
0.3%
Cash ConversionOCF / Net Profit
4.59×
3.80×
TTM Free Cash FlowTrailing 4 quarters
$809.9M
$136.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBOC
IBOC
KNSA
KNSA
Q4 25
$491.1M
$53.9M
Q3 25
$115.2M
$33.7M
Q2 25
$95.5M
$28.1M
Q1 25
$140.5M
$22.3M
Q4 24
$473.9M
$18.8M
Q3 24
$116.5M
$-2.2M
Q2 24
$107.2M
$5.2M
Q1 24
$135.4M
$4.0M
Free Cash Flow
IBOC
IBOC
KNSA
KNSA
Q4 25
$472.9M
$53.3M
Q3 25
$112.2M
$33.0M
Q2 25
$91.6M
$27.9M
Q1 25
$133.1M
$22.2M
Q4 24
$459.8M
$18.6M
Q3 24
$109.6M
Q2 24
$104.9M
Q1 24
$128.9M
$3.9M
FCF Margin
IBOC
IBOC
KNSA
KNSA
Q4 25
217.2%
26.4%
Q3 25
51.5%
18.2%
Q2 25
44.0%
17.8%
Q1 25
67.1%
16.1%
Q4 24
220.8%
15.2%
Q3 24
51.7%
Q2 24
50.5%
Q1 24
62.6%
4.9%
Capex Intensity
IBOC
IBOC
KNSA
KNSA
Q4 25
8.3%
0.3%
Q3 25
1.3%
0.4%
Q2 25
1.9%
0.1%
Q1 25
3.7%
0.1%
Q4 24
6.8%
0.2%
Q3 24
3.3%
0.0%
Q2 24
1.1%
0.0%
Q1 24
3.2%
0.1%
Cash Conversion
IBOC
IBOC
KNSA
KNSA
Q4 25
4.59×
3.80×
Q3 25
1.06×
1.83×
Q2 25
0.95×
1.58×
Q1 25
1.45×
2.61×
Q4 24
4.12×
Q3 24
1.17×
Q2 24
1.11×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons